» Articles » PMID: 37129842

An Appeal for Strengthening Genomic Pathogen Surveillance to Improve Pandemic Preparedness and Infection Prevention: the German Perspective

Abstract

The SARS-CoV-2 pandemic has highlighted the importance of viable infection surveillance and the relevant infrastructure. From a German perspective, an integral part of this infrastructure, genomic pathogen sequencing, was at best fragmentary and stretched to its limits due to the lack or inefficient use of equipment, human resources, data management and coordination. The experience in other countries has shown that the rate of sequenced positive samples and linkage of genomic and epidemiological data (person, place, time) represent important factors for a successful application of genomic pathogen surveillance. Planning, establishing and consistently supporting adequate structures for genomic pathogen surveillance will be crucial to identify and combat future pandemics as well as other challenges in infectious diseases such as multi-drug resistant bacteria and healthcare-associated infections. Therefore, the authors propose a multifaceted and coordinated process for the definition of procedural, legal and technical standards for comprehensive genomic pathogen surveillance in Germany, covering the areas of genomic sequencing, data collection and data linkage, as well as target pathogens. A comparative analysis of the structures established in Germany and in other countries is applied. This proposal aims to better tackle epi- and pandemics to come and take action from the "lessons learned" from the SARS-CoV-2 pandemic.

Citing Articles

[Establishment of genomic pathogen surveillance to strengthen pandemic preparedness and infection prevention in Germany].

Scheithauer S, Dilthey A, Bludau A, Ciesek S, Corman V, Donker T Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2023; 66(4):443-449.

PMID: 36811648 PMC: 9945818. DOI: 10.1007/s00103-023-03680-w.

References
1.
. An integrated national scale SARS-CoV-2 genomic surveillance network. Lancet Microbe. 2020; 1(3):e99-e100. PMC: 7266609. DOI: 10.1016/S2666-5247(20)30054-9. View

2.
Abu-Raddad L, Chemaitelly H, Ayoub H, Yassine H, Benslimane F, Al Khatib H . Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. Clin Infect Dis. 2021; 75(1):e1188-e1191. PMC: 9402694. DOI: 10.1093/cid/ciab909. View

3.
McCrone J, Hill V, Bajaj S, Pena R, Lambert B, Inward R . Context-specific emergence and growth of the SARS-CoV-2 Delta variant. Nature. 2022; 610(7930):154-160. PMC: 9534748. DOI: 10.1038/s41586-022-05200-3. View

4.
Mellmann A, Harmsen D, Cummings C, Zentz E, Leopold S, Rico A . Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology. PLoS One. 2011; 6(7):e22751. PMC: 3140518. DOI: 10.1371/journal.pone.0022751. View

5.
Davies N, Abbott S, Barnard R, Jarvis C, Kucharski A, Munday J . Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021; 372(6538). PMC: 8128288. DOI: 10.1126/science.abg3055. View